#Israel #Prenatal Diagnostics #Pulsenmore #Omer #Home Ultrasound

Pulsenmore Reports Significant Growth in 2025 Financial Results

Pulsenmore Ltd., a leader in home ultrasound technology, has released its financial results for the full year ending December 31, 2025. The company, traded on NASDAQ and TASE under the ticker PLSM, has recorded remarkable growth, celebrating a full-year revenue increase of 374%, surging from $2.6 million in 2024 to $12.5 million in 2025.

This leap in revenue was significantly bolstered by a one-time payment of $9.6 million connected to a settlement with GE Precision Healthcare, an event that resolved previous disputes and conclude all related proceedings. The increase in revenue was accompanied by an improvement in net loss, which decreased to $5 million from $10 million in the preceding year.

Financial Highlights

As of December 31, 2025, Pulsenmore reported $21.7 million in liquid assets, which included $7 million in available cash. The company’s operational performance also saw an enhancement with a gross profit of $10.5 million, marking an impressive gross margin increase to approximately 84%, a notable rise from 37% in 2024. Their operating expenses, however, did increase to $14.4 million reflecting investments aimed at scaling U.S. operations and forming clinical partnerships crucial for future growth.

In discussing these results, Dr. Elazar Sonnenschein, CEO and Founder of Pulsenmore, stated, “2025 was a transformative year for Pulsenmore as we advanced from regulatory achievement to commercial execution. Our focus on scaling our U.S. infrastructure and strengthening operational capabilities positions us for long-term success in the prenatal diagnostics market.”

The company smoothly navigated significant regulatory milestones, securing U.S. FDA clearance for remote-use prenatal ultrasound, paving the way for its entry into the vast U.S. market. Additionally, it achieved CE certification for its Early-Screening pregnancy product across the European Union for early pregnancy scans, starting at 14 weeks gestation.

Operational and Commercial Milestones

Moving forward, Pulsenmore aims to accelerate commercial momentum and enhance recurring revenue streams. With positive feedback from healthcare providers acknowledging the importance of remote ultrasound services, the company appears poised to capitalize on new opportunities in the prenatal diagnostic arena.

Dr. Sonnenschein emphasized that as they transition into 2026, their strategies will be focused on increasing product utilization while maintaining rigorous financial discipline. The company’s outlook remains optimistic, with plans for greater visibility and adoption of their innovative ultrasound technology.

Pulsenmore’s commitment to improving maternal health through remote ultrasound technology aligns with its goal of making prenatal care more patient-centric and accessible. By leveraging advanced imaging technology and telemedicine, they strive to enhance the continuity of care between mothers and healthcare providers.

Looking Forward

The company plans to host a webcast on March 30, 2026, to discuss these results further, providing stakeholders with detailed insights into its operations and future direction. A recording of the meeting will be available for those unable to attend live, which signifies Pulsenmore's commitment to transparency and stakeholder engagement.

As Pulsenmore continues to innovate and expand, its successes in 2025 signal a promising trajectory that could reshape how prenatal diagnostics are approached in the years to come.

For more information on Pulsenmore, visit their website at www.pulsenmore.com.